Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab combinations with immune modulators in advanced solid tumors
NL-OMON44145Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab, utomilumab and ivuxolimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma and 3 more (4 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicity and Confirmed objective response. Planned start Jan 2016; status: withdrawn.
02
Drugs
avelumabutomilumabivuxolimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanomahead and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON44145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44145.